Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

• US 10,342,789 B2
• Filed: 09/23/2016
• Issued: 07/09/2019
• Est. Priority Date: 06/18/2014
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Albrecht, Balazs, Aven, Michael, Lamar, Janine
• Primary Examiner(s): Otton, Alicia L
• Application Number:
  US15/274,259
• Publication Number:
  US 20170007593A1
• Time in Patent Office: 1,019 Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 35/06 Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61M 15/009 using medicine packages with incorporated spraying means, e.g. aerosol cans pocket atomiser of the injector type A61M11/08
• CPC Class Codes: A61M 2250/00 Specially adapted for animals
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

Claims

1. An inhaler device comprising:

a container including a composition comprising;

a solvent comprising a mixture of water and ethanol, wherein ethanol is present in the solvent in an amount of 90-95% V/V;

a glucocorticoid;

a long-acting muscarinic antagonist (LAMA) or a pharmaceutically acceptable salt of the cation thereof and having the following formula;

2. The inhaler device of claim 1, further comprising a pressurized metered dose inhaler or an aqueous/ethanolic droplet inhaler.

3. The inhaler device of claim 1, further comprising an aerosol-generating inhaler.

4. The inhaler device of claim 1, wherein the inhaler device is configured to administer a dose of the LAMA of 100μ

g to 3000μ

g ex inhaler, a dose of the LAMA of 200 μ

g to 2000 μ

g ex inhaler, or a dose of the LAMA of 200 μ

g to 800 μ

g ex inhaler.

5. The inhaler device of claim 1, wherein the glucocorticoid comprises ciclesonide or a pharmaceutically acceptable salt thereof, and the inhaler device is configured to administer a dose of ciclesonide or a pharmaceutically acceptable salt thereof of 100 μ

g to 5000 μ

g ex inhaler.